Vyome Therapeutics Merger with ReShape Lifesciences Creates Vyome Holdings (HIND)

Viveon Health Acquisition Corp. to Merge with Suneva Medical

January 12, 2022

Medical Devices

Suneva Medical, a San Diego–based regenerative aesthetics medical technology company, has entered into a definitive merger agreement with special purpose acquisition company Viveon Health Acquisition Corp. The transaction will combine Suneva with the public SPAC vehicle (NYSE American: VHAQ) to provide growth capital and public-market access for Suneva, with the combined company expected to trade on the NYSE under the symbol "RNEW."

Hexure Acquires Vive

September 25, 2023

Insurance

Hexure, a provider of sales and regulatory automation solutions for the life and annuity industry, has acquired Vive, a quote-and-e-submission platform for term life insurance. The deal combines Hexure's quoting and e-application capabilities with Vive's multi-carrier distribution network (used by more than 20,000 advisors and 55+ BGAs) to create a unified platform for life and annuity distribution.

Viome Life Sciences Acquires Naring Health (including DiscernDX and Foodome)

November 2, 2023

Healthcare Services

Viome Life Sciences has acquired digital health startup Naring Health, including its subsidiaries DiscernDX and Foodome, to expand its capabilities in multi-omics, diagnostics and precision nutrition. The deal brings together microbiome analysis, proteomics and foodomics capabilities to enhance Viome's personalized nutrition and early disease detection offerings.

Lomond Therapeutics Completes Reverse Merger with Venetian-1 and Raises $44M

November 4, 2024

Biotechnology

Lomond Therapeutics completed a reverse merger with Venetian-1 Acquisition Corp., which changed its name to Lomond Therapeutics Holdings, Inc., and closed a $44 million private placement led by existing and new investors. The financing included participation from OrbiMed, Torrey Pines Investment, Deerfield Management, American Financial Group and Heights Capital and will fund advancement of Lomond’s clinical-stage oncology programs (lomonitinib, lonitoclax and a menin inhibitor).

ENDYMED Merges with Majority Shareholder Shanghai Haohai Biological Technology

March 6, 2025

Medical Devices

ENDYMED Ltd completed a full merger with its majority shareholder and China distributor, Shanghai Haohai Biological Technology Co., Ltd, consolidating ownership and operations. The deal is intended to strengthen ENDYMED’s presence in China, streamline the global supply chain, accelerate innovation, and enhance the company’s global market competitiveness.

Vyne Medical Acquires Ahana Health

September 8, 2021

Healthcare Services

Vyne Medical has acquired Ahana Health (also referenced as Ahana Pediatrics) and will integrate its connected-care technology into Vyne’s cloud-based Refyne platform. The acquisition adds collaborative care-planning and virtual care functionality to Refyne to support provider-to-provider and provider-to-patient coordination.